Novanta Inc. · NASDAQ:NOVT
Novanta — Jefferies Global Healthcare Conference 2025
23 slides from Novanta's conference presentation, Nov 18, 2025
Slide 1: A Trusted Partner
A Trusted NOVEMBER 2025 Confidential 1 and Proprietary
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in thi
Slide 3: We Deliver That Matters
We Deliver That Matters Serving as a trusted technology partner to Medical and Advanced Industrial OEMs Confidential 3 and Proprietary
Slide 4: We accelerate innovation and productivity for leading global OEMs
We accelerate innovation and productivity for leading global OEMs in attractive markets ~55% MEDICAL Advanced Surgery Business Model Focus Minimally Invasive Surgery +$975M Robotic Surgery Differentiated Long-term OEM Supplier Precision Medicine (% OF SALES) APPLICATION AREAS Revenue Genomics / Prot
Slide 5: Our strategy drives growth and returns
Our strategy drives growth and returns Win and expand in Asset-light businesses, high growth markets strong margins & cashflows + + Attractive growth Growth Returns Allocate based on platforms cash-on-cash return + + R E V E N UE CASH FLOW MSD/HSD CASH FLOW Organic High Conversion Growth & Algorithm
Slide 6: Entering the next phase in our transformation journey
Entering the next phase in our transformation journey ~2X Revenue ++ +Medical +Subsystems ++ Growth +Recurring Consumables Advanced Industrial +++ ~4X +++ Subsystems Revenue $949M +Embedded Growth ~15% Software +++ Medical ~30% Components Advanced $244M <10% ~30% ~55% 2012 Sales 2024 Sales 2030 Dire
Slide 7: Well-positioned in secular growing end-markets, accelerated by Gen AI
Well-positioned in secular growing end- markets, accelerated by Gen AI END MARKET GROWTH DRIVERS IMPROVED PATIENT OUTCOMES MINIMALLY INVASIVE SURGERY AT LOWER TOTAL COST OF CARE ROBOTIC SURGERY EXPANDING APPLICATIONS ENHANCED PERCEPTION, PHYSICAL AI APPLICATIONS SAFETY AND PRODUCTIVITY PRECISI
Slide 8: Innovative growth platforms in attractive markets
Innovative growth platforms in attractive markets +$4B Size of Additional Market Opportunity by 2030 PUMPS & ROBOTIC PHYSICAL SCAN PRECISION INSUFFLATORS SURGERY AI SYSTEMS MEDICINE Confidential 8 and Proprietary
Slide 9: Expanding our market leadership in gas and fluid management
Expanding our market leadership in gas and fluid management Market Opportunity DOUBLE-DIGIT GROWTH RATE IN MEDICAL CONSUMABLES APPLICATION CAPABILITY +$1B MARKET SIZE BY 2030 Why Novanta Wins Market leader in smoke evacuation insufflation Proprietary algorithms and sensing in fluid and flow manageme
Slide 10: Leading technology provider for robotic surgery applications
Leading technology provider for robotic surgery applications Market Opportunity DOUBLE-DIGIT LONG-TERM MARKET GROWTH RATE $1B MARKET SIZE BY 2030 Why Novanta Wins Customized unique offering Insufflation leadership Position sensing Smart motion control Force/torque sensing PRECISION MOTION AN
Slide 11: Physical AI robotics proprietary solutions focused on advanced safety and sensing
Physical AI robotics proprietary solutions focused on advanced safety and sensing Market Opportunity DOUBLE-DIGIT LONG-TERM MARKET GROWTH RATE ACCELERATED PENETRATION DRIVEN BY GEN AI SENSING Measuring position and MOTION CONTROL $1B MARKET SIZE BY 2030 providing a sense of touch Precise motion via
Slide 12: Early detection of disease drives productivity in healthcare and better patient outcomes
Early detection of disease drives productivity in healthcare and better patient outcomes Market Opportunity HIGH-SINGLE-DIGIT LONG-TERM MARKET GROWTH RATE $0.5B MARKET SIZE BY 2030 Why Novanta Wins PRECISION MOTION RFID READER MACHINE VISION LIGHT ENGINE (sample movement (reagent & (sample scanning
Slide 13: Businesses aligned with end-market growth themes
Businesses aligned with end-market growth themes PRECISION ROBOTICS AND ADVANCED PRECISION MANUFACTURING AUTOMATION SURGERY MEDICINE KEY APPLICATIONS Advanced material Metal-based additive Factory, warehouse & Medical & industrial Robotic surgery Minimally invasive Genomics, proteomics, In vitro dia
Slide 14: High-performance culture is our competitive advantage
High-performance culture is our competitive advantage COHESIVE ENGAGED TEAMS EMPLOYEES Diverse, inclusive, Engage around a shared collaborative: vision and purpose committed to win M&A Talent Owner Mindset and Capital Novanta Allocation Business units with agility, speed, Leverage NOVANTA customer f
Slide 15: Compounding cash flow through attractive acquisitions
Compounding cash flow through attractive acquisitions HOW WE COMPOUND ACQUISITION TRACK RECORD ~ $1.2B 21 HIGH CASH FLOW Capital deployed Transactions REINVEST BUSINESSES FOR NEXT CYCLE LONG-TERM ACQUISITION PIPELINE +$15B Target gross leverage less than 3.0x DEPLOY Aggregate Revenue Disciplined
Slide 16: Improving near-term business momentum
Improving near-term business momentum Strong Order Book Sequential revenue growth momentum $50M in new product sales in 2025 with continued Innovation Pipeline growth and launches in 2026 & 2027 Customer Wins 1) Design Wins up ~50% in high growth markets Manufacturing On track for trade resi
Slide 17: Consistently delivering strong financial results
Consistently delivering strong financial results REVENUE ADJUSTED EBITDA FINANCIAL FRAMEWORK $225M to $978M to $222M $949M $975M $210M Mid to high single-digit organic growth +12% Double-digit reported CAGR +14% growth through CAGR acquisitions 100 bps per year of gross margin expansion $244M $42M S
Slide 18: Delivering Where It Matters Most
Delivering Where It Matters Most Advanced Surgery Precision Medicine Precision Manufacturing Robotics and Automation Confidential 18 and Proprietary
Slide 19: Use of Non-GAAP Measures
Use of Non-GAAP Measures The non-GAAP financial measures used in this presentation are Adjusted EBITDA and Adjusted Gross Profit Margin. The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Co
Slide 20: Non-GAAP Reconciliation
Non-GAAP Reconciliation NINE (in thousands of dollars) TWELVE MONTHS ENDED MONTHS ENDED Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Sep 26, 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 REVENUE Revenue (GAAP) $243,79
Slide 21: Revenue segmentation
Revenue segmentation End Markets(1) Product Types(2) Advanced Robotics & Minimally Invasive Modules ~55% Intelligent & Robotic Surgery Growth profile: MSD Automation Equipment Margin profile: $$$ ~35% ~20% ~15% ~10% ~15% ~30% Advanced Non-invasive Manufacturing ~10% ~10% Intelligent MedTech (IVD, Op
Slide 22: Enabling manufacturing automation and productivity through advanced beam steering
Enabling manufacturing automation and productivity through advanced beam steering Market Opportunity HIGH-SINGLE-DIGIT LONG-TERM MARKET GROWTH RATE $0.4B MARKET SIZE BY 2030 Why Novanta Wins Never-before possible throughput, precision and miniaturization Proprietary integrated solution of hardware a
Slide 23: Mandatory Equity Offering Completed
Mandatory Equity Offering Completed Offering Details Offering Rationale Tangible Equity Unit Security (category of Mandatory Convertible Preferred) Fundamentally, a Mandatory offering is intended to issue stock at a premium to the Offering Size $632.5 million market, with a yield Short-Term Bene
Novanta — Jefferies Global Healthcare Conference 2025 on 6ix